MIMS Australia

What MIMS Australia does

MIMS Australia Pty Ltd is a privately held, Australian-founded pharmaceutical information publisher (established 1963, headquartered in North Sydney) that provides independent, editorially curated drug reference data and clinical decision-support tools to Australian healthcare professionals. The company's core product is the eMIMS platform, offered as eMIMSplus and eMIMSelite (internet-based, accessible across web and mobile) and eMIMS Classic (DVD-based desktop), all delivering Product Information, Consumer Medicine Information, PBS restrictions and pricing, drug interaction checking, and pill identification. A separate MIMS Integrated database is licensed for embedding into 70+ third-party clinical software applications across GP, pharmacy, and hospital settings — including Best Practice, Fred IT (supporting 3,000+ pharmacies), Minfos, Amfac, and Aquarius. Specialty modules include IMgateway (drug-herb and food interactions, developed with the University of Sydney), the MIMS Disperse & Crush Guide, MIMS Drugs4dent (with the University of Melbourne), and IVS/IVS Cloud for veterinary medicine.

The business operates a multi-stream revenue model: named-user digital subscriptions priced $199-$634 per year across tiers, print publications (MIMS Annual at $790, MIMS Abbreviated at $570/year, IVS Annual at $420), optional add-on modules ($135-$280), and OEM-style licensing into clinical software (pricing by negotiation). Go-to-market is hybrid: direct e-commerce via the MIMS e-Store for individual HCPs and SMB buyers, enterprise/licensing sales via the 1800 800 629 customer service line and account team, and embedded channel distribution through 70+ software vendor partners. Editorial coverage is maintained by a team of approximately 40 qualified pharmacists and doctors, producing 170+ monthly updates.

MIMS Australia operates as part of a broader regional network spanning New Zealand (entered 2001) and 13 Asian markets (regional platform launched 2020 under MIMS Asia, including China, India, Southeast Asia, Japan, and Korea), with reported cross-region usage of 400,000+ monthly users on MIMS.com consuming 4 million+ pages. The company has no disclosed external investors or parent ownership and has executed one acquisition (eHealthWise, 2015) as part of product expansion.

Name

MIMS Australia

Legal name

MIMS Australia Pty Ltd

Website

https://mims.com.au

Company type

Private

Founded year

1963

Operating status

Operating

Headcount range

11–50 employees

Short description

MIMS Australia is a private pharmaceutical information publisher (founded 1963, North Sydney) that delivers curated drug reference data, clinical decision support, and PBS pricing tools to 21,000+ Australian healthcare professionals via digital subscriptions, print products, and OEM licensing into 70+ clinical software vendor partners.

Ownership category

akta.pro rank

Product category

Pharmaceutical Reference Software

NAICS

Software Publishers (5132)

akta.pro primary industry

Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH)

akta.pro secondary industry

Medication Therapy Management (MTM) & Clinical Pharmacy Services (HLAFALAH)

Keywords

• Medicines information publishing
• Drug reference database
• Clinical decision support software
• Pharmaceutical reference platform
• Drug interaction checking tools

Headquarters

HQ city

North Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Digital Subscriptions: Subscription-based access to eMIMSplus, eMIMSelite, and eMIMS Classic digital products. Named user licensing with 12-month subscription terms. Prices range from $199 to $634 depending on product tier and user count.
2. Print Publications: Sale of printed reference products including MIMS Annual ($790), MIMS Abbreviated ($570 quarterly), and IVS Annual ($420). Physical books delivered via post.
3. Optional Add-on Modules: Additional subscription modules including IMgateway Drug Herb Interaction Module ($135-$280) and MIMS Disperse & Crush Guide ($180 per site) available for integration with core products.
4. MIMS Integrated Licensing: Licensing of medicine information database for integration into third-party clinical software applications. Contact customer service for pricing as it varies by vendor and organization size.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

MIMS Australia publishes and licenses independent medicines information used by healthcare professionals for prescribing, dispensing, and administering medications. Its core offerings include the eMIMS digital subscription platform (eMIMSplus, eMIMSelite, eMIMS Classic), the MIMS Integrated database for embedding in clinical software, and print references (MIMS Annual, MIMS Abbreviated). Decision support modules cover drug interactions, duplicate therapy, drugs in pregnancy/lactation, drug-allergy, drug-disease, pill identification, and drug-herb interactions (via IMgateway).

Product overview

MIMS Australia is a medicines information company serving healthcare professionals since 1963. The product portfolio consists of three main categories: (1) Core eMIMS digital platform with three deployment options (eMIMSplus/eMIMSelite as internet-based platforms, eMIMS Classic as DVD-based desktop software), all providing Product Information, Consumer Medicine Information, drug interactions, and PBS data; (2) MIMS Integrated database embedded in partner clinical software for over 70 vendors; (3) Decision support modules including Drug Interactions, Duplicate Therapy, Drugs in Pregnancy/Lactation, Drug & Disease, Drug & Allergy, Pill Identification, and IMgateway for herb-food interactions; (4) Print products including MIMS Annual, MIMS Abbreviated, and IVS veterinary references; and (5) Specialty products like MIMS Drugs4dent for dental practitioners.

Differentiator

Problem solved

Functional benefit

Brands

• eMIMS: Digital medicines information software available in multiple platforms: eMIMSplus (internet-based), eMIMSelite (internet-based), and eMIMS Classic (DVD-based). Includes medicine monographs, drug interactions, PBS information, and pill identification.
• eMIMSplus
• eMIMSelite
• MIMS Integrated
• MIMS Dispense & Crush Guide
• IMgateway
• MIMS Drugs4dent
• MIMS Online
• iMIMS
• MIMS Mobile
• MIMS for Android
• MIMS Annual
• MIMS Abbreviated
• IVS (Index of Veterinary Specialities)
• MIMS New Ethicals

Products and services

• eMIMS Digital Medicines Platform Digital subscription providing current Australian Product Information, Consumer Medicine Information, PBS restrictions and pricing, drug interactions, and pill identification, delivered via three platforms: eMIMSplus (internet-based), eMIMSelite (internet-based, single-user), and eMIMS Classic (DVD desktop installation). Targeted at Australian healthcare professionals for prescribing and dispensing decision support.
• MIMS Integrated Drug knowledge base embedded in third-party clinical software applications, providing real-time medicine information, drug interactions, PBS restrictions, and pricing for all registered Australian medicines. Licensed to over 70 clinical software vendors (GP, hospital, pharmacy, specialist) via MIMS Web Services.
• MIMS Annual Hardcover annual printed reference containing full Product Information summaries for doctors and pharmacists. Sold as a one-time/perpetual-license purchase at AUD 790, typically released each July.
• MIMS Abbreviated Quarterly printed publication containing abbreviated prescribing information for healthcare professionals, distributed via post as four issues per annual subscription at AUD 570.
• IVS Annual Annual printed reference for veterinary medicines covering medications for animal health, sold to veterinarians for AUD 420.
• IVS Cloud Web-based subscription providing access to veterinary medicines information for veterinarians, with pricing at AUD 265 per user annually and AUD 209 per additional user.
• MIMS Drugs4dent Web-browser-based subscription product tailored for dental practitioners, providing drug information specific to dental procedures, drug-allergy interactions, pregnancy/lactation recommendations, and pediatric dosing for dental indications. Priced at AUD 199 annually per user.

Quantifiable outcome

• 99.3% of respondents would recommend MIMS to a colleague
• +2 more outcomes

Named customers4 records

Segments8 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• University of Sydney School of PharmacycoreStrategic or Co-development PartnerThe University of Sydney School of Pharmacy developed the IMgateway drug herb and food interaction database, an Australian-first evidence-based complementary medicine interaction module. MIMS partnered with UnityHealth to bring this important work to the desktop of healthcare professionals. The development has been updated and expanded since its inception in 2002.
• University of MelbournecoreStrategic or Co-development PartnerMIMS Australia and the University of Melbourne collaborated to develop MIMS Drugs4dent, a reliable, evidence-based source of drug information specifically for dental practitioners to use at point-of-care.
• UnityHealth Pty LtdcoreTechnology or IntegrationUnityHealth developed the IMgateway solution in partnership with University of Sydney. MIMS partnered with UnityHealth to integrate the Australian evidence-based drug interaction module into eMIMSplus and eMIMSelite products.
• Fred IT GroupcoreTechnology or IntegrationFred IT Group is Australia's largest provider of Pharmacy IT solutions, trusted for 30 years with dedicated local teams supporting over 3,000 pharmacies. Fred Dispense Plus integrates with eMIMSplus providing seamless workflow for pharmacy dispensing.
• 70+ Clinical Software VendorscoreTechnology or IntegrationMIMS database products are integrated into clinical software applications through partnerships with over 70 software vendors across GP, Hospital, Pharmacy, and Specialist vendor categories. These partners use MIMS data as an integral part of their prescribing, dispensing and medication administration software.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Wolters Kluwer (Lexicomp / UpToDate): Global clinical drug information and decision support provider whose Lexicomp and UpToDate products compete directly with MIMS for prescribing, dispensing, and clinical reference workflows in hospitals and among individual practitioners. Operates at much larger scale with broader content depth, but MIMS retains a local-content advantage in Australia.
• IBM Micromedex: Enterprise clinical decision support suite covering drug reference, interactions, IV compatibility, and toxicology, widely embedded in hospital EMRs globally. Directly comparable to MIMS Integrated as an embedded drug database for partner software and institutional customers.
• First Databank (FDB): Provider of drug knowledge bases and clinical decision support that are licensed into pharmacy, EMR, and ePrescribing platforms, overlapping with MIMS Integrated's embedded-database model. FDB is a major global competitor in the same integration layer where MIMS competes with its 70+ software vendor footprint.
• Elsevier ClinicalKey / Gold Standard: Elsevier operates clinical reference platforms (ClinicalKey) and historically drug databases (Gold Standard) that compete with MIMS for institutional subscriptions and integration into clinical workflows. A broad incumbent with adjacent publishing assets that could pressure MIMS in hospital and academic settings.
• Cerner Multum: Cerner (now Oracle Health) operates Multum, a drug knowledge base commonly embedded in hospital information systems and ePrescribing workflows, directly comparable to MIMS Integrated in the embedded clinical software channel. Part of a much broader EHR suite that could disintermediate standalone drug references at large hospital accounts.

Direct peers

• Epocrates: Mobile-first drug reference and clinical decision support tool used by individual healthcare professionals, directly comparable to MIMS's eMIMSplus and eMIMSelite subscriptions in terms of target user, price point, and point-of-care use case. Stronger consumer brand globally, but MIMS has deeper Australian-specific content including PBS data.

Emerging players

• Drugs.com: Consumer- and professional-facing drug information website with interaction checkers, pill identifier, and monographs, comparable in scope to MIMS Online and the consumer-medicine-information components of eMIMS. Serves a global audience but lacks the curated Australian editorial depth and PBS integration.

Regional players

• Pharmaceutical Press (British National Formulary / Martindale): Royal Pharmaceutical Society's publishing arm producing BNF, Martindale, and Stockley drug interaction references, directly comparable to MIMS Annual and MIMS Abbreviated print and digital products. Comparable in editorial authority but UK-centric, positioning it as a regional reference rather than direct competitor in Australia.
• NPS MedicineWise / Australian Prescriber: Australian non-profit provider of independent medicines information, therapeutic guidance, and prescribing resources for GPs and pharmacists. Direct Australian peer in the independent drug reference category, but operates as a non-profit on government funding rather than as a commercial subscription business like MIMS.

Others

• Best Practice Software: Australian clinical software vendor for GP practices that has integrated MIMS data since 2004, making it both a customer and a distribution channel rather than a true competitor. Relevant as a software partner that defines the end-user experience in which MIMS content is consumed.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mims-australia

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIMS Australia